EUK Fundamental Analysis - EUKEDOS SPA

Fundamental Rating

Taking everything into account, EUK scores 1 out of 10 in our fundamental rating. EUK was compared to 31 industry peers in the Health Care Providers & Services industry. There are concerns on the financial health of EUK while its profitability can be described as average. EUK does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year EUK has reported negative net income.

In the past year EUK had a positive cash flow from operations.

In multiple years EUK reported negative net income over the last 5 years.

EUK had a positive operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -0.65%, EUK is not doing good in the industry: 80.65% of the companies in the same industry are doing better.

With a Return On Equity value of -3.97%, EUK is not doing good in the industry: 80.65% of the companies in the same industry are doing better.

With a Return On Invested Capital value of 2.64%, EUK is not doing good in the industry: 70.97% of the companies in the same industry are doing better.

EUK had an Average Return On Invested Capital over the past 3 years of 2.58%. This is below the industry average of 6.10%.

The 3 year average ROIC (2.58%) for EUK is below the current ROIC(2.64%), indicating increased profibility in the last year.

		Industry Rank	Sector Rank
ROA	-0.65%
ROE	-3.97%
ROIC	2.64%

ROA(3y)0.12%

ROA(5y)-0.11%

ROE(3y)0.54%

ROE(5y)-0.64%

ROIC(3y)2.58%

ROIC(5y)2.22%

1.3 Margins

EUK has a better Operating Margin (9.80%) than 90.32% of its industry peers.

EUK's Operating Margin has improved in the last couple of years.

EUK's Gross Margin of 95.00% is amongst the best of the industry. EUK outperforms 96.77% of its industry peers.

EUK's Gross Margin has been stable in the last couple of years.

		Industry Rank	Sector Rank
OM	9.8%
PM (TTM)	N/A
GM	95%

OM growth 3Y-2.47%

OM growth 5Y3.88%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.26%

GM growth 5Y0.24%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EUK has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.

The number of shares outstanding for EUK remains at a similar level compared to 1 year ago.

The number of shares outstanding for EUK remains at a similar level compared to 5 years ago.

Compared to 1 year ago, EUK has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of 0.29, we must say that EUK is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of 0.29, EUK is doing worse than 87.10% of the companies in the same industry.

EUK has a Debt/Equity ratio of 2.94. This is a high value indicating a heavy dependency on external financing.

EUK has a worse Debt to Equity ratio (2.94) than 77.42% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	2.94
Debt/FCF	N/A
Altman-Z	0.29

ROIC/WACC0.56

WACC4.73%

2.3 Liquidity

EUK has a Current Ratio of 0.32. This is a bad value and indicates that EUK is not financially healthy enough and could expect problems in meeting its short term obligations.

Looking at the Current ratio, with a value of 0.32, EUK is doing worse than 87.10% of the companies in the same industry.

A Quick Ratio of 0.32 indicates that EUK may have some problems paying its short term obligations.

EUK's Quick ratio of 0.32 is on the low side compared to the rest of the industry. EUK is outperformed by 87.10% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.32
Quick Ratio	0.32

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

EUK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -260.63%.

EUK shows a small growth in Revenue. In the last year, the Revenue has grown by 4.81%.

Measured over the past years, EUK shows a decrease in Revenue. The Revenue has been decreasing by -0.94% on average per year.

EPS 1Y (TTM)-260.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-475.86%

Revenue 1Y (TTM)4.81%

Revenue growth 3Y6.09%

Revenue growth 5Y-0.94%

Sales Q2Q%3.39%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

EUK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EUK is on the same level as its industry peers.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	9.7

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

EUK does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EUKEDOS SPA

BIT:EUK (12/11/2025, 7:00:00 PM)

0.72

-0.03 (-4%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Providers & Services

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners1.98%

Ins Owner ChangeN/A

Market Cap16.37M

Revenue(TTM)51.30M

Net Income(TTM)-1.15M

AnalystsN/A

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.32
P/FCF	N/A
P/OCF	2.82
P/B	0.56
P/tB	1.84
EV/EBITDA	9.7

EPS(TTM)-0.05

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.67

FCFYN/A

OCF(TTM)0.26

OCFY35.48%

SpS2.26

BVpS1.28

TBVpS0.39

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-0.65%
ROE	-3.97%
ROCE	3.52%
ROIC	2.64%
ROICexc	2.69%
ROICexgc	3.14%
OM	9.8%
PM (TTM)	N/A
GM	95%
FCFM	N/A

ROA(3y)0.12%

ROA(5y)-0.11%

ROE(3y)0.54%

ROE(5y)-0.64%

ROIC(3y)2.58%

ROIC(5y)2.22%

ROICexc(3y)2.64%

ROICexc(5y)2.29%

ROICexgc(3y)3.08%

ROICexgc(5y)2.68%

ROCE(3y)3.43%

ROCE(5y)2.97%

ROICexgc growth 3Y-1.81%

ROICexgc growth 5Y0.32%

ROICexc growth 3Y-1.47%

ROICexc growth 5Y0.29%

OM growth 3Y-2.47%

OM growth 5Y3.88%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.26%

GM growth 5Y0.24%

F-Score5

Asset Turnover0.29

Health

		Industry Rank	Sector Rank
Debt/Equity	2.94
Debt/FCF	N/A
Debt/EBITDA	7.49
Cap/Depr	328.04%
Cap/Sales	40.87%
Interest Coverage	250
Cash Conversion	50.88%
Profit Quality	N/A
Current Ratio	0.32
Quick Ratio	0.32
Altman-Z	0.29

F-Score5

WACC4.73%

ROIC/WACC0.56

Cap/Depr(3y)160.89%

Cap/Depr(5y)115.09%

Cap/Sales(3y)22.9%

Cap/Sales(5y)16.27%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-260.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-475.86%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)4.81%

Revenue growth 3Y6.09%

Revenue growth 5Y-0.94%

Sales Q2Q%3.39%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-10.09%

EBIT growth 3Y3.47%

EBIT growth 5Y2.9%

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-480.42%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-38.86%

OCF growth 3Y20.95%

OCF growth 5Y10.45%

EUKEDOS SPA / EUK.MI FAQ

Can you provide the ChartMill fundamental rating for EUKEDOS SPA?

ChartMill assigns a fundamental rating of 1 / 10 to EUK.MI.

What is the valuation status of EUKEDOS SPA (EUK.MI) stock?

ChartMill assigns a valuation rating of 0 / 10 to EUKEDOS SPA (EUK.MI). This can be considered as Overvalued.

What is the profitability of EUK stock?

EUKEDOS SPA (EUK.MI) has a profitability rating of 4 / 10.

Can you provide the financial health for EUK stock?

The financial health rating of EUKEDOS SPA (EUK.MI) is 1 / 10.

EUKEDOS SPA (EUK.MI) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

EUKEDOS SPA / EUK.MI FAQ

Can you provide the ChartMill fundamental rating for EUKEDOS SPA?

What is the valuation status of EUKEDOS SPA (EUK.MI) stock?

What is the profitability of EUK stock?

Can you provide the financial health for EUK stock?